Krystal Biotech (NASDAQ:KRYS) Stock Price Down 3.1%

Krystal Biotech, Inc. (NASDAQ:KRYS) fell 3.1% during trading on Tuesday . The stock traded as low as $187.62 and last traded at $188.21. 100,366 shares changed hands during trading, a decline of 71% from the average session volume of 350,665 shares. The stock had previously closed at $194.27.

Analyst Upgrades and Downgrades

Several research firms have commented on KRYS. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright boosted their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Trading Up 1.0 %

The firm’s fifty day moving average price is $195.52 and its 200-day moving average price is $179.21. The firm has a market cap of $5.27 billion, a price-to-earnings ratio of 98.65 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Jamison Private Wealth Management Inc. acquired a new stake in Krystal Biotech in the 2nd quarter valued at $28,000. GAMMA Investing LLC raised its holdings in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc bought a new position in Krystal Biotech in the second quarter worth about $28,000. Blue Trust Inc. increased its position in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth about $71,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).